CinCor Pharma to Present at the 32nd Annual Oppenheimer Healthcare Conference
BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, a clinical-stage biopharmaceutical company, announced its participation in the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, a clinical-stage biopharmaceutical company, announced its participation in the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. The management team will present on March 16, 2022, at 10 am EST. CinCor focuses on developing CIN-107, an oral small molecule inhibitor of aldosterone synthase, to treat hypertension and cardio-renal diseases. Investors can contact Oppenheimer & Co. for meeting arrangements during the conference.
Details
News Market Reaction – CINC
The recorded move for CINC in the trading session of this news was +8.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that its management team will present at the 32nd Annual Oppenheimer Healthcare Conference taking place March 15-17, 2022.
| Event: | 32nd Annual Oppenheimer Healthcare Conference |
| Presentation: | Wednesday, March 16, 2022 at 10 am EST |
Management will also meet with investors during the event. Investors interested in meeting with the CinCor management team during the conference should contact their Oppenheimer & Co. representative.
About CinCor
CinCor is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase, for the treatment of hypertension and other cardio-renal diseases.
Contacts:
Terry Coelho
CinCor Pharma, Inc.
EVP, CFO and CBDO
Investors:
Bob Yedid
LifeSci Advisors
ir@CinCor.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.